Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression.

AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1157-62. Unique Identifier : AIDSLINE MED/98407605
Popper SJ; Sankale JL; Thior I; Siby T; Marlink RG; Mboup S; Essex M; Kanki PJ; Harvard AIDS Institute, Harvard School of Public Health, Boston,; Massachusetts 02115, USA.

Abstract: A longitudinal cohort study was conducted to define the prevalence and temporal pattern of antibody response to the HIV-2 virion-associated proteins p26gag and Vpx. One hundred and forty-one asymptomatic HIV-2-infected women were enrolled, and followed for up to 11 years. Eighty-one percent of the subjects had antibodies to p26, and 51% to Vpx; response to these two antigens was not correlated. The response to both proteins was determined early in infection, and remained stable over time. The absence of antibodies to p26 was a highly significant predictor of CDC category IV HIV-related disease (p < 0.01) in both univariate and multivariate analysis. Antibody response to Vpx alone was not associated with disease progression. However, those individuals lacking anti-p26 antibodies, and with anti-Vpx antibodies, were six times more likely to be classified as CDC category IV by the end of the study (p < 0.01). This represents the first identification of virus-specific serological markers for HIV-2-related disease progression.
Keywords: JOURNAL ARTICLE Amino Acid Sequence Blotting, Western Cohort Studies Disease Progression Female Gene Products, gag/*IMMUNOLOGY Human HIV Antibodies/*BLOOD HIV Antigens/GENETICS/*IMMUNOLOGY HIV Infections/*IMMUNOLOGY *HIV-2 Longitudinal Studies Molecular Sequence Data Prostitution Recombinant Fusion Proteins/GENETICS Sequence Alignment Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. Time Factors Viral Regulatory Proteins/*IMMUNOLOGYKWDjournalarticleaminoacidsequenceblotting,westerncohortstudiesdiseaseprogressionfemalegeneproducts,gag/KWDimmunologyhumanhivantibodies/KWDbloodhivantigens/genetics/KWDimmunologyhivinfections/KWDimmunologyKWDhiv-2longitudinalstudiesmolecularsequencedataprostitutionrecombinantfusionproteins/geneticssequencealignmentsupport,uKWDsKWDgov't,non-pKWDhKWDsKWDsupport,uKWDsKWDgov't,pKWDhKWDsKWDtimefactorsviralregulatoryproteins/KWDimmunology
990228
A9920919

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .